Literature DB >> 11553667

gamma-Hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study.

L Ferraro1, S Tanganelli, W T O'Connor, W Francesconi, A Loche, G L Gessa, T Antonelli.   

Abstract

The effect of gamma-hydroxybutyric acid on extracellular glutamate levels in the hippocampus was studied by microdialysis in freely moving rats and in isolated hippocampal synaptosomes. Intra-hippocampal (CA1) perfusion with gamma-hydroxybutyric acid (10 nM-1 mM) concentration-dependently influenced glutamate levels: gamma-hydroxybutyric acid (100 and 500 nM) increased glutamate levels; 100 and 300 microM concentrations were ineffective; whereas the highest 1 mM concentration reduced local glutamate levels. The stimulant effect of gamma-hydroxybutyric acid (100 nM) was suppressed by the locally co-perfused gamma-hydroxybutyric acid receptor antagonist NCS-382 (10 microM) but not by the GABA(B) receptor antagonist CGP-35348 (500 microM). Furthermore, the gamma-hydroxybutyric acid (1 mM)-induced reduction in CA1 glutamate levels was counteracted by NCS-382 (10 microM), and it was also reversed into an increase by CGP-35348. Given alone, neither NCS-382 nor CGP-35348 modified glutamate levels. In hippocampal synaptosomes, gamma-hydroxybutyric acid (50 and 100 nM) enhanced both the spontaneous and K(+)-evoked glutamate efflux, respectively, both effects being counteracted by NCS-382 (100 nM), but not by CGP-35348 (100 microM). These findings indicate that gamma-hydroxybutyric acid exerts a concentration-dependent regulation of hippocampal glutamate transmission via two opposing mechanisms, whereby a direct gamma-hydroxybutyric acid receptor mediated facilitation is observed at nanomolar gamma-hydroxybutyric acid concentrations, and an indirect GABA(B) receptor mediated inhibition predominates at millimolar concentrations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553667     DOI: 10.1046/j.1471-4159.2001.00530.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina.

Authors:  Francesco Pisani; Cinzia Costa; Daniela Caccamo; Emanuela Mazzon; Gaetano Gorgone; Giancarla Oteri; Paolo Calabresi; Riccardo Ientile
Journal:  Exp Brain Res       Date:  2006-01-18       Impact factor: 1.972

Review 2.  Unravelling the brain targets of gamma-hydroxybutyric acid.

Authors:  Vincenzo Crunelli; Zsuzsa Emri; Nathalie Leresche
Journal:  Curr Opin Pharmacol       Date:  2005-12-20       Impact factor: 5.547

3.  GHB-Induced Cognitive Deficits During Adolescence and the Role of NMDA Receptor.

Authors:  R Sircar; L-C Wu; K Reddy; D Sircar; A K Basak
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

Review 4.  gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.

Authors:  Daniel Pardi; Jed Black
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures.

Authors:  Nicolas Gervasi; Zohreh Monnier; Pierre Vincent; Daniele Paupardin-Tritsch; Stuart W Hughes; Vincenzo Crunelli; Nathalie Leresche
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

Review 6.  Behavioral analyses of GHB: receptor mechanisms.

Authors:  Lawrence P Carter; Wouter Koek; Charles P France
Journal:  Pharmacol Ther       Date:  2008-10-29       Impact factor: 12.310

Review 7.  A critical evaluation of the gamma-hydroxybutyrate (GHB) model of absence seizures.

Authors:  Marcello Venzi; Giuseppe Di Giovanni; Vincenzo Crunelli
Journal:  CNS Neurosci Ther       Date:  2014-11-18       Impact factor: 5.243

8.  A Retrospective Metabolomics Analysis of Gamma-Hydroxybutyrate in Humans: New Potential Markers and Changes in Metabolism Related to GHB Consumption.

Authors:  Tingting Wang; Kirstine L Nielsen; Kim Frisch; Johan K Lassen; Camilla B Nielsen; Charlotte U Andersen; Palle Villesen; Mette F Andreasen; Jørgen B Hasselstrøm; Mogens Johannsen
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.